Prostate Cancer and Prostatic Diseases (PROSTATE CANCER P D )

Publisher: Nature Publishing Group

Description

Covers current developments relating to all aspects of prostate cancer research.

  • Impact factor
    2.81
    Show impact factor history
     
    Impact factor
  • 5-year impact
    2.26
  • Cited half-life
    5.10
  • Immediacy index
    0.48
  • Eigenfactor
    0.00
  • Article influence
    0.77
  • Website
    Prostate Cancer and Prostatic Diseases website
  • Other titles
    Prostate cancer and prostatic diseases (Online)
  • ISSN
    1365-7852
  • OCLC
    42458934
  • Material type
    Document, Periodical, Internet resource
  • Document type
    Internet Resource, Computer File, Journal / Magazine / Newspaper

Publisher details

Nature Publishing Group

  • Pre-print
    • Author can archive a pre-print version
  • Post-print
    • Author cannot archive a post-print version
  • Restrictions
    • 6 months embargo
  • Conditions
    • Published source must be acknowledged and DOI cited
    • Must link to publisher version
    • Publisher's version/PDF cannot be used
    • On funding body's archive, author website and institutional repository
    • If funding agency rules apply, authors may post authors version to their relevant funding body's archive, 6 months after publication
    • Several Journals have paid open access options and licenses (see journal homepages)
    • Creative Commons Licenses available for selected titles.
  • Classification
    ​ yellow

Publications in this journal

  • Article: Belhocine T
    Prostate Cancer and Prostatic Diseases 03/2012; 15(1-PMID: 21844889):45-55.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Syndecans are a four-member family of transmembrane heparan sulphate proteoglycans that have different functions in cell signalling, adhesion, cytoskeleton organization, migration, proliferation, and angiogenesis. Several studies investigated the role of syndecan-2 (SDC2) in different carcinomas; however, only one being focused on SDC2 in prostate cancer. SDC2 expression and relationship with established prognostic features were assessed in a cohort of 86 patients treated with radical prostatectomy for clinically localized prostate adenocarcinoma. SDC2 expression was present in the majority of prostate cancers and absent in only 11.6% of cases. SDC2 expression was also recorded in cells of prostatic intraepithelial neoplasia, whereas normal prostatic epithelial tissue and stroma did not express SDC2. SDC2 overexpression in prostate cancer was significantly associated with established features indicative of worse prognosis such as higher preoperative PSA (P=0.011), higher Gleason score (P<0.001), positive surgical margins (P<0.003), and extraprostatic extension of disease (P<0.003). Moreover, expression of SDC2 was also associated with biochemical disease progression on univariate analysis (P<0.001). Study results supported the potential role of SDC2 in prostatic carcinogenesis and cancer progression. Moreover, SDC2 could serve as an additional prognostic marker that might help in further stratifying the risk of disease progression in patients with prostate cancer.Keywords: syndecan-2; prognosis
    Prostate Cancer and Prostatic Diseases 09/2009; 13(1):78-82.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Effective treatment of benign prostatic hyperplasia (BPH) involves not only a reduction of symptom scores and the prevention of serious complications, but also an improvement in overall patient's quality of life and cost effectiveness. There is a paucity of data regarding cost effectiveness when the pharmacologic, the minimally invasive and the surgical treatments of BPH are compared. The potassium-titanyl-phosphate laser prostatectomy seems to be a safe and effective treatment option both in the short and in the long-term run. Preliminary results indicate that photoselective vaporization of the prostate is also a cost-effective method when compared to different minimally invasive treatments and to the transurethral prostatectomy.Keywords: BPH, KTP laser prostatectomy, cost, PVP
    Prostate Cancer and Prostatic Diseases 02/2007;
  • Source
    Prostate Cancer and Prostatic Diseases 02/2007;
  • [Show abstract] [Hide abstract]
    ABSTRACT: African-American men die from prostate cancer (PC) nearly twice as often as white US men and consume about twice as much of the predominant US dietary heterocyclic amine, 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP), a genotoxic rat-prostate carcinogen found primarily in well-cooked chicken and beef. To investigate the hypothesis that PhIP exposure increases PC risk, an ongoing prospective clinic-based study compared PC screening outcomes with survey-based estimates of dietary PhIP intake among 40-70-year-old African-American men with no prior PC in Oakland, CA. They completed food-frequency and meat-cooking/consumption questionnaires and had a prostate-specific antigen (PSA) test and digital-rectal exam. Results for 392 men indicated a 17 (+/-17) ng/kg day mean (+/-1 s.d.) daily intake of PhIP, about twice that of white US men of similar age. PhIP intake was attributable mostly to chicken (61%) and positively associated (R(2)=0.32, P<0.0001) with saturated fat intake. An odds ratio (95% confidence interval) of 31 (3.1-690) for highly elevated PSA > or =20 ng/ml was observed in the highest 15% vs lowest 50% of estimated daily PhIP intake (> or =30 vs < or =10 ng/kg day) among men 50+ years old (P=0.0002 for trend) and remained significant after adjustment for self-reported family history of (brother or father) PC, saturated fat intake and total energy intake. PSA measures were higher in African-American men with positive family history (P=0.007 all men, P<0.0001 highest PSA quartile). These preliminary results are consistent with a positive association between PhIP intake and highly elevated PSA, supporting the hypothesis that dietary intervention may help reduce PC risk.
    Prostate Cancer and Prostatic Diseases 02/2007; 10(3):261-9.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Dual energy X-ray absorptiometry (DEXA) of the hip or spine has been shown to be an effective screening tool for osteoporosis in men undergoing androgen deprivation therapy (ADT) for advanced carcinoma of the prostate. A less expensive alternative to DEXA is the use of peripheral scanners, such as accuDEXA, which measures bone mineral density (BMD) the finger. In this paper, we reviewed 59 patients on ADT who underwent both accuDEXA scan of the non-dominant hand and DEXA scan of the hip. The mean T-scores calculated by the two techniques were similar; however, the individual T-scores correlated poorly with each other. We conclude that men who require ADT for prostate cancer should undergo standard DEXA of the hip for osteoporosis screening.
    Prostate Cancer and Prostatic Diseases 02/2007; 10(1):94-6.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Predominant symptoms in prostate cancer patients are erectile dysfunctions and urinary problems. As decreases of these functions can be attributed to disease and treatment but also to age-related decreases, we conducted a study on a German reference population measuring general quality of life (QoL) as well as prostate-specific symptoms. In cooperation with a German health insurance company, 3000 questionnaires were mailed to a randomly selected sample of men aged 45-75 years. Questionnaires used were the EORTC QLQ-C30 and a prostate-specific module (PSM). One thousand one hundred and fifty questionnaires were returned (response rate: 37.6%). QoL data from this reference population were compared to QoL data from a historical cohort study of prostate cancer patients following either prostatectomy or radiotherapy. In terms of general QoL, the reference population showed similar QoL scores as prostatectomy patients, but better scores than radiotherapy patients. On the PSM, the reference sample showed better overall QoL, but a surprisingly high extent of erectile dysfunction, urinary problems and psychic strain. Taking into account the sensitive topic of this study (sexuality and urinary problems), the response rate is more than satisfying. Older men in our randomly selected, population-based sample do not show perfect erectile and urinary function. These findings should be considered when interpreting QoL data of prostate cancer patients.
    Prostate Cancer and Prostatic Diseases 02/2007; 10(1):52-9.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Adjuvant therapies contribute to the successful treatment of cancer. Our previous reports have shown that combining cryoablation with cytotoxic agents enhances cell death. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a cytotoxic agent that preferentially induces apoptosis in a variety of human cancer cells. Human prostate cancer cells (PC-3) are resistant to many cytodestructive agents, including cryoablation and TRAIL. Here, we evaluated the effects of TRAIL combined with cryoablation on PC-3 and normal prostate (RWPE-1) cell death. Exposure of PC-3 cells to freezing (-10 degrees C) or TRAIL (500 ng/ml) results in minimal cell death, whereas a complete loss of viability is observed with the simultaneous combination. The synergistic effect was found to be due to a marked increase in apoptosis. Western blot analysis revealed a significant level of caspase-8 and -3 cleavage between 12 and 24 h post-exposure. Caspase activation assays provided similar results and also indicated a role for caspase-9. Inhibitors to caspase-8 and -9 along with a pan-caspase inhibitor were incorporated to determine which pathway was necessary for the combined efficacy. Inhibition of caspase-8 significantly blocked the combination-induced cell death compared to cells that did not receive the inhibitor (63% compared to 10% viable). The addition of the caspase-9 inhibitor resulted in only a minimal protection. Importantly, the combination was not effective when applied to normal prostate cells. The results describe a novel therapeutic model for the treatment of prostate cancer and provide support for future in vivo studies.
    Prostate Cancer and Prostatic Diseases 02/2007; 10(2):175-84.

Related Journals